Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Aliment Pharmacol Ther. 2020 Apr 6;51(10):958–967. doi: 10.1111/apt.15698

Table 1.

Demographics, risk factors, and other select variables in patients receiving diagnosis of chronic pancreatitis

Chronic Pancreatitis patients with PERT Use (n = 11265, 30.4%) Chronic Pancreatitis patients with no PERT use (n = 25796, 69.6%) P-value
Age (years – mean(SD)) 50.1 (14.4) 51.7 (15.6) <.0001
Gender, n (%)
 Male 5521 (49.0) 12502 (48.5) .3340
Region, n (%) .0016
 East 2357 (20.9) 5390 (20.9)
 Midwest 3217 (28.6) 7186 (27.9)
 South 3759 (33.4) 9087 (35.2)
 West 1932 (17.2) 4133 (16.0)
Charlson Comorbidity, n (%)
 0 2148 (19.1) 6267 (24.3) <.0001
 1 2542 (22.6) 5704 (22.1)
 2 1698 (15.1) 3851 (14.9)
 3 4877 (43.3) 9974 (38.7)
Alcoholism, n (%) 2814 (25.0) 5076 (19.7) <.0001
Tobacco abuse, n (%) 3394 (30.1) 5566 (21.6) <.0001
Exocrine insufficiency evaluation performed – n (%) 1214 (10.8) 1193 (4.6) <.0001
Diabetes – n (%) 4772 (42.4) 8869 (34.4) <.0001
Osteoporosis or osteopenia – n (%) 682 (6.1) 1347 (5.2) .0012
Fracture diagnosis, n (%) 2002 (17.8) 4143 (16.1) <.0001
Pancreatic surgery performed – n (%) 4024 (35.7) 6349 (24.6) <.0001
Duration of enrollment (months, total) –median (IQR) 55 (30, 78) 55 (31, 78) .8512
Duration of enrollment (months, after CP diagnosis) – median (IQR) 26 (13, 48) 22 (10, 43) <.0001
Saw GI physician– n (%) 5105 (45.3) 6067 (23.5) <.0001
Cystic Fibrosis – n (%) 138 (1.23) 79 (0.31) <.0001